“We believe that our vaccine offers durable protection against COVID-19 and elicits neutralizing activity against the Delta variant,” Paul Stoffels, J&J’s chief scientific officer, said in a statement. “This adds to the robust body of clinical data supporting our single-shot vaccine’s ability to protect against multiple variants of concern.”
The company also said that the immune response produced by the vaccine lasts at least eight months.
“Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time,” Mathai Mammen of Johnson & Johnson said in a statement.
Source: US News
Antibiotic Prescriptions Associated With COVID-19 Outpatient Visits Among Medicare Beneficiaries, April 2020 to April 2021
Outpatient Visits for COVID-19 and Associated Antibiotic Prescriptions Among Medicare Beneficiaries Aged 65 Years or Older, by Setting, US, April 2020 to April 2021. The volume of COVID-19 visits differed by setting: emergency department, 525 608 (45.8% of all visits); office, 295 983 (25.3%); telehealth, 260 261 (22.3%); and urgent care, 77 268 (6.6%).
Source: Journal of American Medical Association Network